426,291 Shares in Repligen Corporation $RGEN Acquired by Bank of America Corp DE

Key Points

• Bank of America acquired 426,291 Repligen shares worth approximately $58.2 million, giving it a 0.76% stake. Institutional investors and hedge funds collectively owned 97.64% of the company.
• Analysts remain generally bullish, with Repligen holding an overall “Buy” rating and an average price target of $168.57; UBS recently raised its target to $225.
• Repligen exceeded quarterly expectations, reporting $0.54 earnings per share versus the $0.45 consensus and $204.13 million in revenue, up 11.9% year over year. Shares opened at $176.89, while the stock trades at a high forward valuation reflected in its 242.32 P/E ratio.

Bank of America Corp DE bought a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 426,291 shares of the biotechnology company's stock, valued at approximately $58,163,000. Bank of America Corp DE owned about 0.76% of Repligen at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. Coldstream Capital Management Inc. lifted its position in shares of Repligen by 5.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company's stock worth $326,000 after purchasing an additional 101 shares during the period. ABS Investment Management LLC acquired a new stake in Repligen during the 2nd quarter worth about $191,016,000. State of Michigan Retirement System raised its position in shares of Repligen by 1.6% in the 1st quarter. State of Michigan Retirement System now owns 12,753 shares of the biotechnology company's stock worth $1,503,000 after acquiring an additional 200 shares in the last quarter. Summitry LLC raised its position in shares of Repligen by 16.3% in the 4th quarter. Summitry LLC now owns 1,741 shares of the biotechnology company's stock worth $285,000 after acquiring an additional 244 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in shares of Repligen by 2.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 10,841 shares of the biotechnology company's stock valued at $1,277,000 after purchasing an additional 300 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity

In other Repligen news, CFO Jason Garland sold 733 shares of the company's stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Weiss Ratings upgraded Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 13th. Wells Fargo & Company increased their price target on Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th. Zacks Research raised shares of Repligen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 30th. UBS Group lifted their price objective on shares of Repligen from $195.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, September 9th. Finally, Benchmark upgraded shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $168.57.

Repligen Stock Performance

Shares of RGEN stock opened at $176.89 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm has a 50-day moving average of $161.50 and a 200-day moving average of $136.81. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The company has a market cap of $9.98 billion, a P/E ratio of 242.32, a P/E/G ratio of 3.23 and a beta of 1.05.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. During the same period in the previous year, the company earned $0.26 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts forecast that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company's portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.